{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:13:10Z","timestamp":1794971590563,"version":"4.9.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Nineteen patients 1 month to &lt;2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5\u201335 days (3 mg\/kg day 1, 1.5 mg\/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild\/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.<\/jats:p>","DOI":"10.1097\/inf.0000000000002568","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T13:29:47Z","timestamp":1581082187000},"page":"305-309","source":"Crossref","is-referenced-by-count":36,"title":["Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to &lt;2 Years of Age With Invasive Candidiasis, Including Candidemia"],"prefix":"10.1097","volume":"39","author":[{"given":"Emmanuel","family":"Roilides","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, 3Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabianne","family":"Carlesse","sequence":"additional","affiliation":[{"name":"Institute of Pediatric Oncology (GRAACC), Universidade Federal de S\u00e3o Paulo (UNIFESP), S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer Inc, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Leister-Tebbe","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Conte","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Raber","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Swanson","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Yan","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal A.","family":"Aram","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Queiroz-Telles","sequence":"additional","affiliation":[{"name":"Department of Public Health, Universidade Federal do Paran\u00e1, Hospital de Clinicas, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Anidulafungin A8851008 Pediatric Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jpeds.2013.04.034","article-title":"Neurodevelopmental outcome of extremely low birth weight infants with Candida infection.","volume":"163","author":"Adams-Chapman","year":"2013","journal-title":"J Pediatr"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/INF.0000000000002237","article-title":"A Prospective, Open-label Study to assess the safety, tolerability and efficacy of anidulafungin in the treatment of invasive candidiasis in children 2 to <18 years of age.","volume":"38","author":"Roilides","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/376906","article-title":"A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis.","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/clpt.2011.26","article-title":"Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.","volume":"89","author":"Cohen-Wolkowiez","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/gut.34.4.565","article-title":"Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?","volume":"34","author":"Rhodes","year":"1993","journal-title":"Gut"},{"key":"R9-20230912","first-page":"189","article-title":"Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant.","volume":"17","author":"Kicker","year":"2012","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:34:03Z","timestamp":1694543643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002568","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}